Eli Lilly close to buying gene editing firm Verve for $1.3 bln- FT

Eli Lilly is reportedly in advanced discussions to acquire gene editing company Verve Therapeutics for up to $1.3 billion, consisting of $1 billion upfront and $300 million in milestone payments, according to the Financial Times. The deal, which values Verve at roughly twice its market capitalization, aims to integrate Verve's gene editing technology into Eli Lilly's drug development pipeline, furthering Lilly's acquisition strategy following its recent purchases of Scorpion Therapeutics and SiteOne Therapeutics.

Analysis

Eli Lilly and Company (NYSE:LLY) is reportedly in advanced discussions to acquire gene editing start-up Verve Therapeutics Inc (NASDAQ:VERV) for up to $1.3 billion, consisting of $1 billion upfront and $300 million in performance-based milestones. This potential acquisition values Verve at approximately double its market capitalization of just over $500 million prior to the announcement, causing Verve's shares to surge nearly 73% to $10.76 in aftermarket trading. The strategic rationale for Eli Lilly, the world's largest drugmaker, is to integrate Verve's gene editing technology into its experimental drug pipeline, continuing its active M&A strategy in 2024 which has already seen the $2.5 billion acquisition of Scorpion Therapeutics and $1 billion for SiteOne Therapeutics. This move underscores Lilly's efforts to leverage its strong performance, driven by its successful diabetes and weight loss drugs Mounjaro and Zepbound, to expand its technological capabilities and future product offerings, thereby defying broader industry headwinds. The reported deal carries a 'strongly positive' sentiment (overall score 0.8, LLY 0.75, VERV 0.9), indicating market optimism regarding the synergistic potential and Lilly's continued expansion.

Key Decisions for Investors

• Investors should consider this acquisition as a positive strategic move by Eli Lilly to bolster its long-term growth prospects by entering the promising field of gene editing, leveraging its current financial strength.
• For Verve Therapeutics shareholders, the substantial premium offered in the proposed deal presents a significant value realization opportunity, contingent upon the successful closure of the transaction.
• Monitor Eli Lilly's execution on integrating Verve's technology and the subsequent progress of its gene editing pipeline, as successful outcomes will be critical for justifying the acquisition premium and enhancing Lilly's innovation profile.